Suivi du patient après transplantation cardiaque: monitoring et adaptation de l'immunosuppression [Monitoring and adjustment of immunosuppression after heart transplantation].
Détails
ID Serval
serval:BIB_20823C4A01A1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Suivi du patient après transplantation cardiaque: monitoring et adaptation de l'immunosuppression [Monitoring and adjustment of immunosuppression after heart transplantation].
Périodique
Revue Médicale Suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2009
Volume
5
Numéro
205
Pages
1214-1220
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review Publication Status: ppublish
Résumé
Heart transplantation remains the best therapeutic option for the treatment of end-stage heart failure. However, good survival rates can be obtained only if patients are closely monitored, particularly for their immunosuppressive regimens. Currently, a triple-drug regimen usually based on calcineurin-inhibitors (cyclosporin A or tacrolimus), anti-proliferative agents and steroids is used in most recipients. New agents such as the mTOR inhibitors, a more recently developed class of immunosuppressive drugs, can also be used in some patients. The aim of this article is to review currently used immunosuppressive regimens after heart transplantation, and to propose some individualized options depending on specific patient characteristics and recent pharmacological developments in the field.
Mots-clé
Chronic Disease, Clinical Trials as Topic, Cyclosporine/administration & dosage, Drug Therapy, Combination, Glucocorticoids/administration & dosage, Graft Rejection/prevention & control, Graft Survival/drug effects, Heart Failure/surgery, Heart Transplantation, Humans, Immunosuppression/methods, Immunosuppressive Agents/administration & dosage, Meta-Analysis as Topic, Monitoring, Immunologic/methods, Mycophenolic Acid/administration & dosage, Mycophenolic Acid/analogs & derivatives, Protein Kinases/drug effects, Randomized Controlled Trials as Topic, Sirolimus/administration & dosage, Survival Analysis, T-Lymphocytes/drug effects, TOR Serine-Threonine Kinases, Tacrolimus/administration & dosage, Treatment Outcome
Pubmed
Création de la notice
20/07/2009 10:39
Dernière modification de la notice
20/08/2019 13:56